等待开盘 12-20 09:30:00 美东时间
+0.025
+2.00%
Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mild-to-moderate COVID-19 patients.
12-17 22:26
Traws Pharma announces rigosertib shows 80% overall response rate in treating RDEB-associated cutaneous SCC, with 50% complete responses, marking a significant advancement in a rare and aggressive disease.
06-03 11:00
Traws Pharma received FDA feedback on tivoxavir marboxil (TXM) for bird flu and seasonal flu, including the use of the Animal Rule. Positive preclinical data supports TXM's potential as a single-dose treatment, with plans for further development and stockpiling to address potential pandemics.
05-27 12:00
Three proposals, including a reverse stock split, were submitted and approvedTraws Board subsequently approved a 1-for-25 reverse stock splitTraws' shares expected to begin trading on a split-adjusted basis on September
2024-09-18 04:06
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(4.87) per share. The company reported $57.00 thousand in sales this quarter. This is a 5.00 percent decrease over sales of $60.00 thousand the same period last year.
2024-08-15 19:19